Published in Clin Cancer Res on September 01, 1996
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
The Arabidopsis AMP1 gene encodes a putative glutamate carboxypeptidase. Plant Cell (2001) 1.52
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A (2005) 1.49
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol (2006) 1.48
Overview of prostate-specific membrane antigen. Rev Urol (2004) 1.34
Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem (2012) 1.34
Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med (2009) 1.31
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med (2012) 1.29
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther (2008) 1.18
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res (2012) 1.17
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.09
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem (2007) 1.08
Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res (2014) 1.08
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res (2008) 1.07
Prostate-specific membrane antigen-based therapeutics. Adv Urol (2011) 1.06
Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther (2014) 1.04
Identification of gene interactions associated with disease from gene expression data using synergy networks. BMC Syst Biol (2008) 1.04
Extracellular proteases as targets for drug development. Curr Protein Pept Sci (2009) 1.02
Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. FASEB J (2009) 1.01
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.98
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci U S A (1998) 0.88
Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorg Med Chem Lett (2011) 0.88
Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol (2005) 0.88
Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family. J Mol Evol (2006) 0.86
Opposing roles of folate in prostate cancer. Urology (2013) 0.86
Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One (2012) 0.84
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett (2012) 0.81
Promoter analysis of human glutamate carboxypeptidase II. Brain Res (2007) 0.80
[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). J Med Chem (2015) 0.79
Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts. Int J Clin Exp Med (2013) 0.79
Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane. J Carcinog (2006) 0.79
Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen. PLoS One (2013) 0.79
Molecular identification of β-citrylglutamate hydrolase as glutamate carboxypeptidase 3. J Biol Chem (2011) 0.78
Cancer stratification by molecular imaging. Int J Mol Sci (2015) 0.78
Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett (2007) 0.78
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
The Small Molecule Hyperphyllin Enhances Leaf Formation Rate and Mimics Shoot Meristem Integrity Defects Associated with AMP1 Deficiency. Plant Physiol (2016) 0.76
ALTERED MERISTEM PROGRAM1 suppresses ectopic stem cell niche formation in the shoot apical meristem in a largely cytokinin-independent manner. Plant Physiol (2015) 0.76
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Aptamers in Therapeutics. J Clin Diagn Res (2016) 0.75
Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget (2017) 0.75
Evaluation of coliform tests for chlorinated secondary effluents. J Water Pollut Control Fed (1973) 5.51
Synthetic lac operator DNA is functional in vivo. Nature (1976) 5.36
Intermittent reinforcement of operant behavior in children. J Exp Anal Behav (1958) 5.09
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J (2000) 4.11
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Presence of an SH2 domain in the actin-binding protein tensin. Science (1991) 4.03
Dynamics and segregation of cell-matrix adhesions in cultured fibroblasts. Nat Cell Biol (2000) 3.99
The general affinity of lac repressor for E. coli DNA: implications for gene regulation in procaryotes and eucaryotes. Cell (1975) 3.73
Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry (1996) 3.65
Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem (1996) 3.63
T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A (1998) 3.61
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem (1980) 3.49
Integrin dynamics and matrix assembly: tensin-dependent translocation of alpha(5)beta(1) integrins promotes early fibronectin fibrillogenesis. J Cell Biol (2000) 3.13
Identification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro (2014) 3.10
Beta-galactosidase. Rates of synthesis and degradation of incomplete chains. J Biol Chem (1972) 3.06
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00
An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J Biol Chem (2001) 2.95
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med (1999) 2.92
Cytochalasins inhibit nuclei-induced actin polymerization by blocking filament elongation. J Cell Biol (1980) 2.74
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Cytochalasin B, its interaction with actin and actomyosin from muscle (cell movement-microfilaments-rabbit striated muscle). Proc Natl Acad Sci U S A (1972) 2.68
Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. Nature (1981) 2.63
The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut (1999) 2.60
Lipid A modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12. Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate. J Biol Chem (1999) 2.56
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
GATA-1 expression pattern can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development (1997) 2.38
Specific interaction of vinculin with alpha-actinin. Biochem Biophys Res Commun (1987) 2.34
A comparison of lac repressor binding to operator and to nonoperator DNA. Biochem Biophys Res Commun (1975) 2.32
Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PMRA-dependent 4-amino-4-deoxy-L-arabinose, and phosphoethanolamine incorporation. J Biol Chem (2001) 2.30
A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data. Pharmacogenomics J (2010) 2.30
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J (1998) 2.29
Bacterial activity in South Pole snow. Appl Environ Microbiol (2000) 2.28
Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J (1997) 2.26
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Toward a resolution of the introns early/late debate: only phase zero introns are correlated with the structure of ancient proteins. Proc Natl Acad Sci U S A (1998) 2.16
The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol (2001) 2.15
Zebrafish pigmentation mutations and the processes of neural crest development. Development (1996) 2.14
Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion. Mol Biol Cell (1999) 2.10
Purification and initial characterization of a protein from skeletal muscle that caps the barbed ends of actin filaments. J Biol Chem (1986) 2.08
Neurological impairment in violent schizophrenic inpatients. Am J Psychiatry (1989) 2.07
Chemical and pharmacological evaluation of different ayurvedic preparations of iron. J Ethnopharmacol (1999) 2.07
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity (1997) 2.04
Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging (2006) 2.03
Actin polymerization induced by a motility-related high-affinity cytochalasin binding complex from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 1.99
Timing, propagation, coordination, and effect of esophageal shortening during peristalsis. Gastroenterology (1997) 1.94
The RAD50 gene, a member of the double strand break repair epistasis group, is not required for spontaneous mitotic recombination in yeast. Curr Genet (1990) 1.93
Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. Nat Biotechnol (1998) 1.92
Instant MR labeling of stem cells using magnetoelectroporation. Magn Reson Med (2005) 1.88
Biochemical studies on the mode of action of cytochalasin B. Cytochalasin B binding to red cell membrane in relation to glucose transport. J Biol Chem (1974) 1.86
High-affinity interaction of vinculin with actin filaments in vitro. Cell (1982) 1.83
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol (2000) 1.82
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. J Ethnopharmacol (2003) 1.77
Oxygen requirement for the biosynthesis of the S-2-hydroxymyristate moiety in Salmonella typhimurium lipid A. Function of LpxO, A new Fe2+/alpha-ketoglutarate-dependent dioxygenase homologue. J Biol Chem (2000) 1.76
The 200-MeV proton therapy project at the Paul Scherrer Institute: conceptual design and practical realization. Med Phys (1995) 1.75
Biphasic calcium phosphate bioceramics: preparation, properties and applications. J Mater Sci Mater Med (2003) 1.74
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol (2001) 1.70
Closure mechanisms of laryngeal vestibule during swallow. Am J Physiol (1992) 1.67
An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature (2001) 1.65
Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. Br J Psychiatry (1997) 1.65
Experimental characterization and physical modelling of the dose distribution of scanned proton pencil beams. Phys Med Biol (2005) 1.64
Shape, volume, and content of the deglutitive pharyngeal chamber imaged by ultrafast computerized tomography. Gastroenterology (1993) 1.63
A zebrafish model for hepatoerythropoietic porphyria. Nat Genet (1998) 1.62
Specificity of the effects of cytochalasin B on transport and motile processes. Proc Natl Acad Sci U S A (1978) 1.61
Accumulation of a polyisoprene-linked amino sugar in polymyxin-resistant Salmonella typhimurium and Escherichia coli: structural characterization and transfer to lipid A in the periplasm. J Biol Chem (2001) 1.60
Acute stroke in the very elderly: epidemiological features, stroke subtypes, management, and outcome in Martinique, French West Indies. Stroke (2003) 1.58
Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology (2001) 1.58
Synthesis of Sch 29482--a novel penem antibiotic. J Antimicrob Chemother (1982) 1.57
Pharyngeal clearance during swallowing: a combined manometric and videofluoroscopic study. Gastroenterology (1992) 1.56
Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem (1995) 1.52
Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF on survival of a random flap in the rat. Br J Plast Surg (2003) 1.50
Modification of bacterial artificial chromosomes through chi-stimulated homologous recombination and its application in zebrafish transgenesis. Proc Natl Acad Sci U S A (1998) 1.49
Intensity modulated proton therapy: a clinical example. Med Phys (2001) 1.49
A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A (1999) 1.49
Promoter analysis in living zebrafish embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl Acad Sci U S A (1997) 1.47
Evaluation of chemical constituents and free-radical scavenging activity of Swarnabhasma (gold ash), an ayurvedic drug. J Ethnopharmacol (2002) 1.46
Reconstitution of interactions between tyrosine kinases and the high affinity IgE receptor which are controlled by receptor clustering. EMBO J (1995) 1.46
Direct observation of sub-picosecond equilibration of excitation energy in the light-harvesting antenna of Rhodospirillum rubrum. Biophys J (1995) 1.46
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc (1999) 1.46
High affinity cytochalasin B binding to red cell membrane proteins which are unrelated to sugar transport. J Biol Chem (1977) 1.46
Beta-galactosidase: alpha-complementation of a deletion mutant with cyanogen bromide peptides. Biochem Biophys Res Commun (1970) 1.46
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood (1992) 1.46
Dihydrocytochalasin B. Biological effects and binding to 3T3 cells. J Cell Biol (1978) 1.45
Trends in blind and low vision registrations in Taipei City. Eur J Ophthalmol (2008) 1.45
An alternative to DRGs. A clinically meaningful and cost-reducing approach. Med Care (1986) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Pregnancy outcome following genetic amniocentesis at 11-14 versus 16-19 weeks' gestation. Obstet Gynecol (1996) 1.44
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr (1997) 1.43
Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology (2006) 1.43
Biochemical studies on the mode of action of cytochalasin B. Preparation of (3H)cytochalasin B and studies on its binding of cells. J Biol Chem (1974) 1.43